Related references
Note: Only part of the references are listed.Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency
Visanu Thamlikitkul et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Development and validation of liquid chromatography tandem mass spectrometry method quantitative determination of polymyxin B1, polymyxin B2, polymyxin B3 and isoleucine-polymyxin B1 in human plasma and its application in clinical studies
Kim H. Hee et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2017)
Role of Renal Drug Exposure in Polymyxin B-Induced Nephrotoxicity
Pooja Manchandani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Characterization of Polymyxin B Biodistribution and Disposition in an Animal Model
Pooja Manchandani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Comparative Pharmacokinetic Profiling of Different Polymyxin B Components
Pooja Manchandani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
In Vitro Assessment and Multicenter Cohort Study of Comparative Nephrotoxicity Rates Associated with Colistimethate versus Polymyxin B Therapy
Kady Phe et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Colistin and Polymyxin B: Peas in a Pod, or Chalk and Cheese?
Roger L. Nation et al.
CLINICAL INFECTIOUS DISEASES (2014)
Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches
Ilias Karaiskos et al.
EXPERT OPINION ON PHARMACOTHERAPY (2014)
Population Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients: Implications for Selection of Dosage Regimens
Ana M. Sandri et al.
CLINICAL INFECTIOUS DISEASES (2013)
Clinical management of infections caused by multidrug-resistant Enterobacteriaceae
Mercedes Delgado-Valverde et al.
THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE (2013)
Drugs of Last Resort? The Use of Polymyxins and Tigecycline at US Veterans Affairs Medical Centers, 2005-2010
Benedikt Huttner et al.
PLOS ONE (2012)
In Vitro Potency of Various Polymyxin B Components
Vincent H. Tam et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2011)
Variability of polymyxin B major components in commercial formulations
Jie He et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2010)
The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic
Laura S. Elias et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Performance in population models for count data, part I: maximum likelihood approximations
Elodie L. Plan et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2009)
Performance in population models for count data, part II: A new SAEM algorithm
Radojka Savic et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2009)
Parenteral polymyxin B use in patients with multidrug-resistant gram-negative bacteremia and urinary tract infections: A retrospective case series
Andrew A. Pastewski et al.
ANNALS OF PHARMACOTHERAPY (2008)
Pharmacokinetics of Intravenous Polymyxin B in Critically Ill Patients
Alexandre P. Zavascki et al.
CLINICAL INFECTIOUS DISEASES (2008)
Pharmacokinetics of polymyxin B1 in patients with multidrug-resistant Gram-negative bacterial infections
Andrea L. H. Kwa et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2008)
Polymyxin antibiotics for gram-negative infections
Tamra M. Arnold et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2007)
Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group
R Bellomo et al.
CRITICAL CARE (2004)